Circio Holding Valuation

Is CRNA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CRNA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CRNA (NOK0.71) is trading below our estimate of fair value (NOK31.28)

Significantly Below Fair Value: CRNA is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for CRNA?

Key metric: As CRNA is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for CRNA. This is calculated by dividing CRNA's market cap by their current earnings.
What is CRNA's PE Ratio?
PE Ratio3.4x
EarningsNOK 9.50m
Market CapNOK 32.26m

Price to Earnings Ratio vs Peers

How does CRNA's PE Ratio compare to its peers?

The above table shows the PE ratio for CRNA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average64.3x
AZT ArcticZymes Technologies
147.2x73.8%NOK 681.3m
NSB NeuroScientific Biopharmaceuticals
14.7xn/aAU$4.8m
532041 Hindustan Bio Sciences
72.1xn/a₹104.7m
NAVA Navamedic
23.1x29.6%NOK 453.9m
CRNA Circio Holding
3.4x61.2%NOK 32.3m

Price-To-Earnings vs Peers: CRNA is good value based on its Price-To-Earnings Ratio (3.4x) compared to the peer average (56.8x).


Price to Earnings Ratio vs Industry

How does CRNA's PE Ratio compare vs other companies in the European Biotechs Industry?

5 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.27.0x16.1%
CRNA Circio Holding
3.4x61.2%US$2.84m
CRNA 3.4xIndustry Avg. 27.0xNo. of Companies5PE020406080100+
5 CompaniesEstimated GrowthMarket Cap
Industry Avg.27.0x16.1%
CRNA Circio Holding
3.4x61.2%US$2.84m
No more companies

Price-To-Earnings vs Industry: CRNA is good value based on its Price-To-Earnings Ratio (3.4x) compared to the European Biotechs industry average (26.8x).


Price to Earnings Ratio vs Fair Ratio

What is CRNA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CRNA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio3.4x
Fair PE Ratio19.5x

Price-To-Earnings vs Fair Ratio: CRNA is good value based on its Price-To-Earnings Ratio (3.4x) compared to the estimated Fair Price-To-Earnings Ratio (19.5x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CRNA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentNOK 0.71
NOK 2.00
+181.7%
50.0%NOK 3.00NOK 1.00n/a2
Dec ’25NOK 0.74
NOK 2.00
+170.3%
50.0%NOK 3.00NOK 1.00n/a2
Nov ’25NOK 1.16
NOK 2.00
+73.2%
50.0%NOK 3.00NOK 1.00n/a2
Oct ’25NOK 0.70
NOK 2.00
+184.1%
50.0%NOK 3.00NOK 1.00n/a2
Sep ’25NOK 1.30
NOK 3.00
+130.8%
66.7%NOK 5.00NOK 1.00n/a2
Aug ’25NOK 2.33
NOK 3.00
+28.8%
66.7%NOK 5.00NOK 1.00n/a2
Jul ’25NOK 2.46
NOK 12.00
+387.8%
91.7%NOK 23.00NOK 1.00n/a2
Jun ’25NOK 3.06
NOK 12.00
+292.2%
91.7%NOK 23.00NOK 1.00n/a2
May ’25NOK 2.50
NOK 48.00
+1,820.0%
107.7%NOK 120.00NOK 1.00n/a3
Apr ’25NOK 6.00
NOK 48.00
+700.0%
107.7%NOK 120.00NOK 1.00n/a3
Mar ’25NOK 6.40
NOK 70.50
+1,001.6%
70.2%NOK 120.00NOK 21.00n/a2
Feb ’25NOK 6.78
NOK 70.50
+940.0%
70.2%NOK 120.00NOK 21.00n/a2
Jan ’25NOK 7.20
NOK 57.00
+691.7%
78.4%NOK 120.00NOK 21.00n/a3
Dec ’24NOK 6.75
NOK 57.00
+744.4%
78.4%NOK 120.00NOK 21.00NOK 0.743
Nov ’24NOK 6.23
NOK 57.00
+815.1%
78.4%NOK 120.00NOK 21.00NOK 1.163
Oct ’24NOK 10.80
NOK 75.00
+594.4%
60.0%NOK 120.00NOK 30.00NOK 0.702
Sep ’24NOK 15.30
NOK 75.00
+390.2%
60.0%NOK 120.00NOK 30.00NOK 1.302
Aug ’24NOK 17.40
NOK 75.00
+331.0%
60.0%NOK 120.00NOK 30.00NOK 2.332
Jul ’24NOK 17.10
NOK 75.00
+338.6%
60.0%NOK 120.00NOK 30.00NOK 2.462
Jun ’24NOK 14.07
NOK 99.00
+603.6%
21.2%NOK 120.00NOK 78.00NOK 3.062
May ’24NOK 18.30
NOK 99.00
+441.0%
21.2%NOK 120.00NOK 78.00NOK 2.502
Apr ’24NOK 21.81
NOK 99.00
+353.9%
21.2%NOK 120.00NOK 78.00NOK 6.002
Mar ’24NOK 24.30
NOK 99.00
+307.4%
21.2%NOK 120.00NOK 78.00NOK 6.402
Feb ’24NOK 29.70
NOK 99.00
+233.3%
21.2%NOK 120.00NOK 78.00NOK 6.782
Jan ’24NOK 32.88
NOK 99.00
+201.1%
21.2%NOK 120.00NOK 78.00NOK 7.202
Dec ’23NOK 35.40
NOK 99.00
+179.7%
21.2%NOK 120.00NOK 78.00NOK 6.752

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 23:18
End of Day Share Price 2024/12/30 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Circio Holding ASA is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Arvid NecanderCarnegie Investment Bank AB
Geir HolomDNB Markets
Jonas PeciulisEdison Investment Research